Google
TNGX — TANGO THERAPEUTICS INC (Healthcare >> Biotechnology)
TNGX FAQ
What is TNGX's P/E ratio?
TANGO THERAPEUTICS INC (TNGX) currently trades at a P/E ratio of 195.79.
What is TNGX's ROE?
TANGO THERAPEUTICS INC reports a Return on Equity (ROE) of -27.39%.
What is TNGX's dividend yield?
TANGO THERAPEUTICS INC offers a dividend yield of 0.00%.
What is TNGX's Deepscope Quality Score?
Deepscope rates TNGX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TNGX?
Deepscope's AI Timing Score for TNGX is 69 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does TNGX belong to?
TANGO THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 22.15
Price
0.68
(3.17%)
Day Change
|
|
|---|
TNGX, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 84 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 22.15 |
| PBV / Sector |
7.94 / 4.58
|
| Earning Per Share | -0.76 |
| PE / Sector |
195.79 / 17.10
|
| PEG or PE/Growth / Sector |
-20.63 / 0.52
|
| Average 1M Daily Value |
58.83 M
|
| Average 1W Daily Value |
52.84 M
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:11:40 |
| Symbol | TNGX |
| Name | TANGO THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 144.65 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3,109.93 / 8,655.90 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 201 Brookline Avenue, Boston, MA, United States, 02215
Phone: 857 320 4900
Website: https://www.tangotx.com
Employees: 137
Sector: Healthcare >> Biotechnology
Description: Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
